Moderna - MRNA Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
View MRNA analyst ratings or view top-rated stocks.

11 equities research analysts have issued 12 month price objectives for Moderna's shares. Their MRNA share price forecasts range from $77.00 to $395.00. On average, they predict the company's share price to reach $227.75 in the next year. This suggests a possible upside of 68.8% from the stock's current price.
View analysts price targets for MRNA or view top-rated stocks among Wall Street analysts.

Moderna's stock was trading at $253.98 on January 1st, 2022. Since then, MRNA stock has decreased by 46.9% and is now trading at $134.90.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MRNA earnings forecast.

Moderna, Inc. (NASDAQ:MRNA) posted its quarterly earnings data on Wednesday, August, 3rd. The company reported $5.24 EPS for the quarter, topping the consensus estimate of $4.73 by $0.51. The company had revenue of $4.73 billion for the quarter, compared to analyst estimates of $3.95 billion. Moderna had a net margin of 61.12% and a trailing twelve-month return on equity of 94.76%. Moderna's revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the company earned $6.46 EPS.

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Johnson & Johnson (JNJ), Alibaba Group (BABA) and Zoom Video Communications (ZM).

(MRNA) raised $499 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 21,700,000 shares at a price of $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Moderna trades on the NASDAQ under the ticker symbol "MRNA."

Moderna's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.45%), State Street Corp (3.71%), Flagship Pioneering Inc. (3.24%), Theleme Partners LLP (1.60%), Price T Rowe Associates Inc. MD (0.85%) and Northern Trust Corp (0.84%). Insiders that own company stock include David W Meline, Dustin A Moskovitz, Edwin M Kania Jr, Elizabeth G Nabel, Jennifer Ling Lee, Juan Andres, Lorence H Kim, Lori M Henderson, Lori M Henderson, Lori M Henderson, Mark D Mclaughlin, Noubar Afeyan, Paul Sagan, Peter Barton Hutt, Shannon Thyme Klinger, Stephane Bancel, Stephen Hoge, Tal Zvi Zaks, Ventures Fund Iv Gene Flagship and W Don Cornwell.
View institutional ownership trends.

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRNA stock can currently be purchased for approximately $134.90.

Moderna (NASDAQ:MRNA) has a market capitalization of $53.66 billion and generates $18.47 billion in revenue each year. The company earns $12.20 billion in net income (profit) each year or $32.81 on an earnings per share basis.

The company employs 2,700 workers across the globe.

Moderna's mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.modernatx.com. The company can be reached via phone at (617) 714-6500 or via email at ir@modernatx.com.